Pfizer extends King tender offer until January
NEW YORK (Reuters) - Pfizer Inc (PFE.N) is extending its offer to buy King Pharmaceuticals Inc KG.N to January 21, the world's largest drugmaker said on Wednesday.
About 47 percent of outstanding King shares were tendered as of December 14, Pfizer said.
Pfizer agreed in October to buy King for $3.6 billion to shore up earnings ahead of the evaporation of revenue from Lipitor, its biggest product.
Pfizer, which is digesting last year's $67 billion acquisition of Wyeth, said it would use cash to pay $14.25 a share for King -- a 40 percent premium over King's closing share price before the deal was announced.
The deal would expand Pfizer's presence in the market for pain drugs by adding King's pain portfolio to products such as Lyrica and Celebrex.
(Reporting by Ransdell Pierson. Editing by Robert MacMillan)
NEW YORK - U.S. stocks finished mostly higher on Friday, with the S&P 500 closing at a record after more jobs than expected were created in February and January's figure was revised higher.
- U.S. small businesses borrowed more money in January than they did a year earlier, signaling continued growth in the economy despite a spate of cold weather that has been blamed for weakness in many other indicators of activity.
BEIJING/HONG KONG - China reiterated its opposition on Thursday to a European Union plan to limit airline carbon dioxide emissions and called for talks to resolve the issue a day after its major airlines refused to pay any carbon costs under the new law.